Overview of Lipanthyl Supra

Property	Description
Active ingredient	Fenofibrate
Form	Film-coated tablet (Microcoated)
Pharmacological class	Fibrates (Antilipemic agent)
General purpose	Rebalancing blood lipids (TG, VLDL, HDL)
Origin	Synthetic compound

What Type of Medicine is Lipanthyl Supra?

Lipanthyl Supra is a prescription-only medication classified as an antilipemic agent, primarily used to improve blood lipid profiles. Its active ingredient is Fenofibrate, a synthetic compound derived from fibric acid, which places it within the established fibrate pharmacological class. This class of agents is distinct from other lipid-lowering drugs like statins, offering a targeted approach to managing specific lipid imbalances as an adjunct to diet and exercise.

Fenofibrate is identified as a peroxisome proliferator-activated receptor alpha (PPARα) activator. The medicine is clinically recognized for its action on a specific regulatory pathway within the body responsible for controlling fat metabolism.

Composition and Form: The Fenofibrate Tablet

Lipanthyl Supra is supplied as a film-coated tablet designed for oral administration. The primary substance is Fenofibrate, which is often presented in a specialized microcoated formulation that aids in optimal absorption within the digestive system. This microcoated feature is a differentiating characteristic from older, standard Fenofibrate tablets, and is engineered for enhanced bioavailability.

This medication is a single-ingredient product, containing only Fenofibrate as the therapeutic component. After ingestion, the body rapidly converts the inactive Fenofibrate prodrug into its biologically effective molecule, Fenofibric acid, which is responsible for the therapeutic action on fat metabolism.

General Purpose: Rebalancing Blood Lipids

The general purpose of Lipanthyl Supra is to correct hyperlipidaemia, which is the medical term for high levels of fats in the blood. Its core function is to achieve systemic rebalancing of the patient's lipid profile. The primary action of fibrates is to significantly reduce elevated levels of triglycerides and Very Low-Density Lipoprotein (VLDL), while simultaneously working to increase the concentration of beneficial High-Density Lipoprotein (HDL). This ability to target multiple lipid fractions makes it a valuable option in typical use scenarios involving mixed dyslipidemia.

Regulatory References

What side effects are possible with Lipanthyl Supra?

Possible side effects and safety information

Fenofibrate, the active ingredient in Lipanthyl Supra, is associated with a defined spectrum of adverse reactions and safety risks documented in official regulatory labeling. These effects are classified by the body system impacted and their expected frequency, based on regulatory standards.

Common Adverse Reactions (occurring in at least 1 in 100 patients) frequently involve Gastrointestinal Disorders, including abdominal pain, nausea, vomiting, diarrhea, and flatulence. Additionally, headache and increases in serum transaminases (indicators of liver function) are classified as common.

Uncommon Reactions include the development of cholelithiasis (gallstones) and an increased risk of myopathy (muscle disease).

Serious Adverse Reactions are explicitly documented and require strict monitoring. These include severe Hepatotoxicity (drug-induced liver injury), Rhabdomyolysis (severe muscle breakdown), Pancreatitis, and Venothromboembolic Disease (e.g., Deep Vein Thrombosis and Pulmonary Embolism). Severe cutaneous adverse drug reactions like Stevens-Johnson syndrome (SJS) are also listed in regulatory labeling.

Safety Considerations and Restrictions The medicine is contraindicated in specific patient populations, including those with active liver disease, pre-existing gallbladder disease, or severe renal impairment (eGFR < 30 mL/min/1.73 m^2). The risk of muscle toxicity (myopathy and rhabdomyolysis) is noted as elevated in special populations, particularly geriatric patients and those with renal impairment. Monitoring of liver function tests is specified periodically, especially during the first year of administration, and hematologic changes may be observed following treatment initiation.

Overdose and Emergency Response

When an overdose of Lipanthyl Supra (Fenofibrate) is suspected, immediate medical attention is required to initiate necessary emergency procedures and ensure patient safety. Official government regulatory documents establish that there is no specific treatment or antidote known for Fenofibrate overdose. Consistent with this, the regulatory guidance does not list specific acute clinical signs or unique manifestations that characterize an overdose presentation.

The protocol for managing an overdose is centered on general supportive care of the patient. This care package is indicated to include the continuous monitoring of vital signs and observation of clinical status under medical supervision. To limit further systemic exposure, medical professionals may decide to proceed with procedures aimed at the elimination of unabsorbed drug, such as emesis or gastric lavage, if these interventions are deemed medically appropriate. A key procedural constraint stated in regulatory documents is that hemodialysis should not be considered for drug removal, as the drug's high plasma protein binding prevents effective elimination by this method. These actions define the mandated response to a Fenofibrate overdose.

Therapeutic Uses of Lipanthyl Supra

What Lipanthyl Supra Treats: Main Uses and Benefits

Lipanthyl Supra is commonly used to help with Abnormal Blood Fat Concentrations when dietary changes and exercise alone have been insufficient. The core benefit is to provide support that helps ease the overall symptom burden related to these imbalances, including high levels of triglycerides and VLDL-cholesterol, and low levels of beneficial HDL-cholesterol. This action supports patients with conditions like severe hypertriglyceridemia or mixed dyslipidemia, and may be part of symptomatic management that addresses risk factors associated with vascular health concerns. The medication is used as an adjunct to diet and other non-pharmacological treatments for several conditions.

The medication is commonly used to manage lipid abnormalities in patients with Type 2 Diabetes Mellitus or Metabolic Syndrome where persistent metabolic abnormalities create noticeable physiological strain. It is relevant for easing visible symptoms related to cholesterol accumulation, such as xanthomas.

“This therapy supports the patient during difficult episodes by easing distress associated with persistent metabolic abnormalities.”

Quick Fact: Support for High Blood Fats

The medication is applied in clinical settings involving acute or unstable symptom patterns where additional support is appropriate, providing supportive relief when symptoms interfere with routine activities.

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Lipanthyl Supra

Lipanthyl Supra (fenofibrate) is subject to strict eligibility rules based on regulatory guidelines, defining the specific populations who may use the medicine and those who are excluded.

Contraindicated Populations

Use of this medicine is absolutely prohibited (contraindicated) for individuals with the following conditions, as stated in official labeling:

Severe Chronic Kidney Disease: Creatinine clearance less than 30 mL/min/1.73 m^2.
Hepatic Insufficiency: Including biliary cirrhosis or unexplained persistent liver function abnormality.
Known Sensitivities: Hypersensitivity to fenofibrate, or a history of photoallergy/phototoxicity from fibrates or ketoprofen, or allergies to peanut/soya excipients.
Gallbladder and Pancreatic Disease: Pre-existing gallbladder disease or chronic/acute pancreatitis (unless due to severe hypertriglyceridemia).

Restricted and Excluded Groups

Population Group	Eligibility Status	Rationale (Regulatory Basis)
Children and Adolescents (< 18 yrs)	Not Recommended	Safety and efficacy have not been established.
Pregnant Women	Conditional Use	Only after a careful risk-benefit assessment due to inadequate human data.
Breastfeeding Women	Not Recommended	A risk to the nursing infant cannot be excluded.
Moderate Renal Impairment	Conditional Use	Requires close monitoring and specific dose adjustment.

Eligibility is primarily determined by organ function and known allergies. Use is limited to adults who do not possess any contraindicating medical conditions or sensitivities.

What should I know about interactions with other medicines?

Lipanthyl Supra (Fenofibrate) has documented interactions that fall into distinct regulatory categories, primarily affecting co-administered medicines through altered exposure or additive pharmacodynamic risk.

Pharmacodynamic Risk and Additive Effects

Co-administration with HMG-CoA Reductase Inhibitors (statins) or colchicine is associated with an increased pharmacodynamic risk of myopathy and rhabdomyolysis. This muscle-related risk is formally noted to be heightened in geriatric patients and those with existing renal impairment.

Altered Exposure and Clearance

Fenofibrate causes a pharmacokinetic interaction leading to the potentiation of coumarin anticoagulants such as Warfarin. This potentiation is documented to cause a prolongation of the International Normalized Ratio (INR) and requires the anticoagulant dose to be reduced under careful monitoring. Fenofibrate is also classified as a mild-to-moderate inhibitor of CYP2C9 and other CYP enzymes, which can alter the clearance of drugs metabolized by these pathways. The co-administration with immunosuppressants like Cyclosporine carries a documented risk of deterioration of renal function.

Administration Timing and Substance Restrictions

Fenofibrate must be administered with a specific timing separation from bile acid binding resins (e.g., Colestyramine). A mandatory separation of at least one hour before or four to six hours after the resin is required to prevent documented absorption impediment. Patients are formally advised to avoid drinking alcohol during treatment due to potential risk factors related to hepatotoxicity.

Mechanism of Action

Lipanthyl Supra's mechanism of action is rooted in the selective activation of the Peroxisome Proliferator-Activated Receptor alpha (PPARalpha), a nuclear receptor that serves as a genetic switch controlling lipid metabolism in the liver. This agonism initiates changes in the transcription of genes that regulate lipid metabolism through two primary domains:

PPARalpha Agonism: Regulating Gene Expression

The drug's active form, Fenofibric acid, acts as a PPARalpha agonist, directly modulating the transcription of genes involved in fat processing. This molecular activation modulates the genetic instructions for proteins that regulate triglycerides and cholesterol, resulting in alterations to plasma lipid fractions.

Enhancing Triglyceride Breakdown and Clearance

Activation of PPARalpha results in the upregulation of Lipoprotein Lipase (LPL) activity and the downregulation of its inhibitor, Apolipoprotein C-III (ApoC-III). This dual action accelerates the catabolism (breakdown and removal) of Very Low-Density Lipoprotein (VLDL) particles and other triglyceride-rich lipoproteins from the plasma, resulting in a reduction in circulating triglycerides.

Modulating HDL Synthesis and Particle Quality

The mechanism also supports the production of key proteins, ApoA-I and ApoA-II, which are essential components of High-Density Lipoprotein (HDL). This mechanism contributes to the formation of HDL particles and is associated with a shift in circulating LDL particles from the small, dense type to a larger, more buoyant size, altering the physical characteristics of the fat-carrying particles.

Dosage and Administration Information

How to Use Lipanthyl Supra

Lipanthyl Supra (Fenofibrate) is administered via the oral route as a film-coated tablet. The standard regimen for most adult patients involves taking the medication once daily. The specific strengths used are typically the 160 mg or 145 mg tablet, which also represents the maximum recommended dose for once-daily use.

Administration Instructions

The tablet is designed to be swallowed whole with a glass of water and must not be crushed, broken, dissolved, or chewed. Recommendations regarding food vary by formulation: the tablet may be taken during a meal, while other specialized formulations permit administration without regard to meals.

Treatment is intended for long-term use as an adjunct to diet. However, treatment is discontinued if an adequate therapeutic response is not achieved after two months of treatment at the maximum daily dose.

Population-Specific Dosing

Specific dosage modifications are explicitly required for certain patient populations. For elderly patients (aged 65 and older), the usual adult dose is applied unless kidney function is reduced. For patients with mild to moderate renal impairment (estimated glomerular filtration rate between 30 and <60 mL/min), a reduced dose is mandatory; an initial low dose, such as 48 mg or 54 mg once daily, is necessary. Conversely, use is generally contraindicated or avoided in cases of severe renal impairment and is not recommended for the pediatric population due to limited data. A specific procedural condition requires that if the patient is also taking a bile acid binding resin, Fenofibrate must be administered at least 1 hour before or 4 to 6 hours after the resin to avoid affecting absorption.

Recent Clinical Evidence

Recent Clinical Evidence Overview

Lipanthyl Supra contains fenofibrate, an active ingredient that belongs to the fibrate class of medications. Clinical research on fenofibrate primarily focuses on its role as an adjunctive therapy to diet for managing elevated lipid levels, including severe hypertriglyceridemia (high triglycerides) and primary hypercholesterolemia (high cholesterol) or mixed dyslipidemia.

Core Efficacy and Lipid Modification

Fenofibrate's actions are mediated by activating peroxisome proliferator-activated receptor alpha (PPAR alpha). Studies demonstrate that fenofibrate therapy is associated with several changes in the lipid profile:

Triglycerides (TG): A substantial decrease in plasma triglyceride levels is consistently observed.
HDL-Cholesterol: Fenofibrate is typically associated with a moderate increase in high-density lipoprotein cholesterol (HDL-C), often referred to as 'good' cholesterol.
LDL-Cholesterol: Effects on low-density lipoprotein cholesterol (LDL-C) are variable, but studies suggest a moderate reduction in total cholesterol and apolipoprotein B.

Safety and Tolerability Profile

Large-scale clinical trials have continuously examined the safety profile of fenofibrate. The most frequently reported side effects in patients include mild gastrointestinal issues, such as stomach pain, nausea, and flatulence. The research also explores the potential for more serious, though uncommon, adverse events:

Muscle Events: Myopathy (muscle weakness/pain) and rhabdomyolysis are rare but known risks, particularly when fenofibrate is used in combination with HMG-CoA reductase inhibitors (statins). Close monitoring of muscle symptoms is advised.
Hepatotoxicity: Elevation of liver enzymes has been observed, requiring periodic monitoring of liver function tests during treatment.

Combination Therapy Findings

Research has specifically investigated the use of fenofibrate as an add-on to statin therapy, particularly in patients with atherogenic dyslipidemia (characterized by high TG and low HDL-C). While major trials have yielded mixed results regarding the overall reduction of cardiovascular events, subgroup analyses suggest a potential benefit for reducing major cardiovascular events in patients with this specific lipid pattern. Furthermore, dedicated trials have explored fenofibrate's effect on microvascular complications, suggesting a potential role in reducing the risk of diabetic retinopathy progression.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Lipanthyl Supra (FAQ)

Q: Is Lipanthyl Supra the same as other fibrates like Tricor?

Lipanthyl Supra is a brand name medication that belongs to the fibrate class of medicines. Fibrates share the same general mechanism of action for lowering lipids. According to the official product information, Lipanthyl Supra often contains a microcoated formulation designed to potentially improve the way the body absorbs the active ingredient, Fenofibrate, compared to standard or older versions.

Q: Does Lipanthyl Supra interact with common blood pressure medications?

Regulatory information indicates that Fenofibrate is a mild inhibitor of certain enzymes in the body (such as CYP2C9), which has the potential to alter how other medicines are cleared or affect their levels. Additionally, patients with existing kidney issues, who are often treated for high blood pressure, may require careful monitoring due to a noted increased risk of muscle toxicity.

Q: Can older adults safely use Lipanthyl Supra?

The official documentation indicates that the usual adult regimen is typically applied to elderly patients (age 65 and older) unless reduced kidney function requires consideration of a lower dose. Official documents specifically note that the risk of muscle toxicity is elevated in this population, necessitating monitoring during treatment.

Q: What ingredients are in the Lipanthyl Supra pill besides the main drug?

The tablet contains the active ingredient, Fenofibrate, along with several inactive ingredients, also known as excipients. These include common substances like lactose monohydrate and soy lecithin. Patients with known allergies to excipients, such as soya or peanut oil derivatives, are formally contraindicated from using the product.

Q: What should I do if I experience an unusual skin rash while taking Lipanthyl Supra?

Severe skin reactions, including conditions like Stevens-Johnson Syndrome, have been reported in official documents. Regulatory guidance associated with severe reactions indicates the medicine should be discontinued, and a healthcare professional should be consulted for appropriate treatment.

Q: Can people with diabetes safely use Lipanthyl Supra?

Studies and official information indicate that Lipanthyl Supra is approved for use in adult patients, including those with type 2 diabetes. Clinical trials have specifically investigated its potential effects on microvascular complications, such as diabetic retinopathy, in this patient group.

Q: Is Lipanthyl Supra a generic drug or a brand name?

Lipanthyl Supra is the brand name for this product. The active ingredient it contains is Fenofibrate, which is the molecule that performs the therapeutic action and is also available in generic forms.

Q: What happens to the Lipanthyl Supra once it is metabolized in the body?

After ingestion, Fenofibrate is rapidly converted into its biologically active molecule, Fenofibric acid. This active form is primarily eliminated from the body via the kidneys (urine). The time it takes for the concentration of Fenofibric acid in the body to decrease by half is approximately 20 hours.

Q: Why do official documents mention 'secondary treatment' for high cholesterol?

Official documents often refer to the medicine as an 'adjunct to diet' or 'adjunctive therapy.' This means the medicine is intended to be used as a supportive or secondary intervention. The initial and primary method for managing high cholesterol is through lifestyle changes, including diet and exercise.

Q: Are there published studies about Lipanthyl Supra's effect on kidney disease progression?

Studies conducted on fenofibrate show it can cause an initial, reversible reduction in kidney function (eGFR). However, long-term clinical trial data has also shown an association with a reduction in the rate of eGFR decline and lower rates of albuminuria in specific subgroups of diabetic patients.

Q: What happens if I miss a dose of Lipanthyl Supra?

Official dosing information describes the protocol for a missed dose as taking it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the patient should resume the regular schedule. The regulatory guidance specifies that double or extra doses must not be taken.

Q: Does Lipanthyl Supra interact with common pain relievers like ibuprofen or aspirin?

Fenofibrate may increase the blood levels and effects of some Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as ibuprofen, which requires caution. The official product information generally advises patients to be monitored for interactions with antiplatelet agents like aspirin.

Q: If my blood test numbers look normal, do I still need to take Lipanthyl Supra?

Lipid levels are intended to be monitored periodically by a healthcare professional throughout treatment. Regulatory guidance states that if blood lipid levels fall significantly below the targeted range, reducing the dosage may be considered. Continuing or stopping any therapy requires consultation with a qualified healthcare professional.

Q: Can Lipanthyl Supra interact with herbal supplements?

The official labeling instructs that patients inform their healthcare professional about all supplements and herbal products they take. Some specific supplements have been generally noted as potentially increasing the risks of muscle problems when used with fibrates.

Q: Does Lipanthyl Supra affect sleep or cause insomnia?

According to official safety profiles, insomnia (difficulty sleeping) has been reported as a common adverse effect in some clinical trials.

Q: What are the signs of an overdose of Lipanthyl Supra?

Official regulatory information states that there is no specific treatment available for an overdose of fenofibrate. In cases of overdose, official guidance notes that general supportive care, including monitoring of vital signs, is indicated. Special procedures like hemodialysis are not considered effective.

Q: Can I take Lipanthyl Supra if I have a thyroid condition?

Official warnings and precautions note that patients with certain thyroid problems, specifically hypothyroidism (underactive thyroid), may have an increased risk of myopathy (muscle problems) when taking fibrates and require increased monitoring.

Q: Is it a problem if I take other vitamins while on Lipanthyl Supra?

The official labeling instructs that patients inform their healthcare professional about all vitamins they are taking. Caution is specifically advised regarding drugs that affect Vitamin K, as fenofibrate can potentiate the effects of these types of medicines.

How should Lipanthyl Supra be stored and disposed of?

Storage Requirements

Lipanthyl Supra (fenofibrate 160 mg) must be stored at a controlled room temperature and should not exceed 30 C. The product must be kept in its original package to ensure protection from moisture and light, as mandated by the labeling to maintain the 3-year shelf-life stability. It is an explicit safety requirement that the medication be kept out of the sight and reach of children.

Disposal Instructions

Disposal of any unused or expired Lipanthyl Supra must be conducted in accordance with local regulatory requirements. The official instructions advise against discarding the medicine into wastewater, such as flushing it down the toilet or pouring it down a drain. The preferred method for safe disposal involves utilizing community drug take-back programs.

Lipanthyl Supra